Different Brands of Intravenous Immunoglobulin for Primary Immunodeficiencies: How to Choose the Best Option for the Patient? Publisher Pubmed



Abolhassani H^{1, 2} ; Asgardoon MH¹ ; Rezaei N^{1, 3} ; Hammarstrom L² ; Aghamohammadi A¹
Source: Expert Review of Clinical Immunology Published:2015

Abstract

Immunoglobulin (IG) replacement therapy has served as lifesaving treatment in primary immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients with PID require IG replacement to maintain their health during the course of disease. It is estimated that about one-third of IG products is used for replacement therapy in these patients. On the other hand, the introduction of newer IG preparations is continuing to improve and extend the quality of life in PID patients. Because of the options available including concentrations, formulations, osmolality, product stabilizers, sodium concentration, anti-infective activity, IgA content and pH, it is important to match the PID patients complications with potential side effects associated with the composition of a particular IG product. The purpose of this review is to present the clinical differences of intravenous IG among the various preparations regarding PID patients. © 2015 Taylor & Francis.